Patient and treatment characteristics by cardiac complications
| . | CAD (n = 107) . | Arrhythmia (n = 85) . | Valve disease (n = 78) . | Pericardial disease (n = 9) . | ||||
|---|---|---|---|---|---|---|---|---|
| n . | % . | n . | % . | n . | % . | n . | % . | |
| Sex | ||||||||
| Female | 27 | 25.2 | 38 | 44.7 | 44 | 56.4 | 4 | 44.4 |
| Male | 80 | 74.8 | 47 | 55.3 | 34 | 43.6 | 5 | 55.6 |
| Age at diagnosis, y | ||||||||
| < 20 | 16 | 14.9 | 12 | 14.1 | 16 | 20.5 | 4 | 44.4 |
| 20-29 | 32 | 29.9 | 27 | 31.8 | 26 | 33.3 | 3 | 33.3 |
| 30-39 | 24 | 22.4 | 14 | 16.5 | 13 | 16.7 | 1 | 11.1 |
| 40-49 | 15 | 14 | 13 | 15.3 | 9 | 11.5 | 1 | 11.1 |
| ≥ 50 | 20 | 18.7 | 19 | 22.3 | 14 | 17.9 | 0 | 0 |
| Median age at cardiac events, y (range) | 48 (20-75) | 50 (14-87) | 49 (23-76) | 44 (18-62) | ||||
| Clinical stage | ||||||||
| I | 28 | 26.2 | 24 | 28.2 | 25 | 32.1 | 0 | 0 |
| II | 59 | 55.1 | 54 | 63.5 | 47 | 60.3 | 8 | 88.9 |
| III | 19 | 17.8 | 5 | 5.9 | 5 | 6.4 | 1 | 11.1 |
| IV | 1 | 0.9 | 2 | 2.4 | 1 | 1.3 | 0 | 0 |
| Follow-up time, y | ||||||||
| > 5 | 102 | 95.3 | 83 | 97.6 | 77 | 98.7 | 9 | 100.0 |
| > 10 | 95 | 88.8 | 75 | 88.2 | 73 | 93.6 | 9 | 100.0 |
| > 15 | 80 | 74.8 | 62 | 72.9 | 64 | 82.1 | 8 | 88.9 |
| Treatment | ||||||||
| RT alone | 82 | 76.6 | 58 | 68.2 | 58 | 74.4 | 7 | 77.8 |
| RT + chemotherapy | 25 | 23.4 | 27 | 31.8 | 20 | 25.6 | 2 | 22.2 |
| Median dose, Gy | 40.00 | 40.00 | 39.90 | 40.00 | ||||
| RT field | ||||||||
| Mantle alone | 15 | 14.0 | 21 | 24.7 | 19 | 24.4 | 1 | 11.1 |
| MPA | 65 | 60.7 | 57 | 67.1 | 50 | 64.1 | 7 | 77.8 |
| TNI | 25 | 23.4 | 6 | 7.1 | 9 | 11.5 | 1 | 11.1 |
| Involved field | 2 | 1.9 | 1 | 1.2 | 0 | 0 | 0 | 0 |
| Doxorubicin | ||||||||
| No | 104 | 97.2 | 78 | 91.8 | 72 | 92.3 | 9 | 100.0 |
| Yes | 3 | 2.8 | 7 | 8.2 | 6 | 7.7 | 0 | 0 |
| . | CAD (n = 107) . | Arrhythmia (n = 85) . | Valve disease (n = 78) . | Pericardial disease (n = 9) . | ||||
|---|---|---|---|---|---|---|---|---|
| n . | % . | n . | % . | n . | % . | n . | % . | |
| Sex | ||||||||
| Female | 27 | 25.2 | 38 | 44.7 | 44 | 56.4 | 4 | 44.4 |
| Male | 80 | 74.8 | 47 | 55.3 | 34 | 43.6 | 5 | 55.6 |
| Age at diagnosis, y | ||||||||
| < 20 | 16 | 14.9 | 12 | 14.1 | 16 | 20.5 | 4 | 44.4 |
| 20-29 | 32 | 29.9 | 27 | 31.8 | 26 | 33.3 | 3 | 33.3 |
| 30-39 | 24 | 22.4 | 14 | 16.5 | 13 | 16.7 | 1 | 11.1 |
| 40-49 | 15 | 14 | 13 | 15.3 | 9 | 11.5 | 1 | 11.1 |
| ≥ 50 | 20 | 18.7 | 19 | 22.3 | 14 | 17.9 | 0 | 0 |
| Median age at cardiac events, y (range) | 48 (20-75) | 50 (14-87) | 49 (23-76) | 44 (18-62) | ||||
| Clinical stage | ||||||||
| I | 28 | 26.2 | 24 | 28.2 | 25 | 32.1 | 0 | 0 |
| II | 59 | 55.1 | 54 | 63.5 | 47 | 60.3 | 8 | 88.9 |
| III | 19 | 17.8 | 5 | 5.9 | 5 | 6.4 | 1 | 11.1 |
| IV | 1 | 0.9 | 2 | 2.4 | 1 | 1.3 | 0 | 0 |
| Follow-up time, y | ||||||||
| > 5 | 102 | 95.3 | 83 | 97.6 | 77 | 98.7 | 9 | 100.0 |
| > 10 | 95 | 88.8 | 75 | 88.2 | 73 | 93.6 | 9 | 100.0 |
| > 15 | 80 | 74.8 | 62 | 72.9 | 64 | 82.1 | 8 | 88.9 |
| Treatment | ||||||||
| RT alone | 82 | 76.6 | 58 | 68.2 | 58 | 74.4 | 7 | 77.8 |
| RT + chemotherapy | 25 | 23.4 | 27 | 31.8 | 20 | 25.6 | 2 | 22.2 |
| Median dose, Gy | 40.00 | 40.00 | 39.90 | 40.00 | ||||
| RT field | ||||||||
| Mantle alone | 15 | 14.0 | 21 | 24.7 | 19 | 24.4 | 1 | 11.1 |
| MPA | 65 | 60.7 | 57 | 67.1 | 50 | 64.1 | 7 | 77.8 |
| TNI | 25 | 23.4 | 6 | 7.1 | 9 | 11.5 | 1 | 11.1 |
| Involved field | 2 | 1.9 | 1 | 1.2 | 0 | 0 | 0 | 0 |
| Doxorubicin | ||||||||
| No | 104 | 97.2 | 78 | 91.8 | 72 | 92.3 | 9 | 100.0 |
| Yes | 3 | 2.8 | 7 | 8.2 | 6 | 7.7 | 0 | 0 |